Noiman Silvia 4
4 · Eloxx Pharmaceuticals, Inc. · Filed Jun 29, 2018
Insider Transaction Report
Form 4
Noiman Silvia
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2018-06-06$0.00/sh+349,400$210→ 490,789 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-06-06−349,400→ 0 totalExercise: $0.00Exp: 2024-04-26→ Common Stock (349,400 underlying)
Footnotes (3)
- [F1]The option was issued pursuant to the Company's Eloxx Pharmaceuticals Ltd. Share Ownership and Option Plan (2013) and was priced at Israeli New Shekel 0.0020. This amount reflects the U.S. dollar equivalent of the exercise price as of the transaction date using an exchange rate of 1:3.5736, as reported by Bloomberg.
- [F2]Represents the total number of shares owned by the Reporting Person as of the date of filing.
- [F3]The option was fully vested and exercisable as of October 26, 2016.